Jiangsu Recbio Technology (HKG:2179) said its experimental shingles vaccine REC610 showed a generally favorable safety and immunogenicity profile in a Phase III clinical trial.
The vaccine is being developed to prevent shingles in adults aged 40 and above, according to a Thursday Hong Kong bourse filing.
Recbio plans to discuss the product application and review process with China's National Medical Products Administration and Center for Drug Evaluation. Marketing approval has not yet been granted.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments